A Republican bill with 1 Democratic cosponsor · See the cosponsor
Last activity — Referred to the House Committee on Financial Services.
In committee
Introduced and handed to a committee in the chamber it started in.
The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.
Its path through Congress
- Introduced
- In Committee
What this bill would do
The bill is known as the Biotech Investment National Security Act of 2026 or the BINSA Act. It amends title VIII of the Defense Production Act of 1950 to change the definitions of prohibited technology and notifiable technology. The legislation addresses concerns that United States capital flowing to Chinese biotechnology companies accelerates China's acquisition of pharmaceutical intellectual property. It requires the Secretary of the Treasury to issue a rule defining biotechnology parameters within one year. Additionally, the bill mandates that the Secretary of Defense submit a report assessing how United States capital flows into China's biotechnology sector affect national security and military readiness.
Yes· 3 of 4
- Scored +8
Does this make patent and copyright rules fairer?
The legislation protects United States pharmaceutical intellectual property and prevents its strategic transfer to foreign adversaries.
- Scored +6
Does this give the federal government more power?
The bill expands federal oversight and regulatory authority regarding outbound investments in the biotechnology sector.
- Scored +5
Does this make the country readier for the next outbreak?
The bill enhances national biosecurity and pharmaceutical supply chain independence by restricting outbound investments in biotechnology.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
-
Section 3 updates the Defense Production Act of 1950 to include biotechnology, such as pharmaceutical products and biological products, under prohibited and notifiable technologies, which helps protect United States security and pharmaceutical supply chains from strategic dependency.
-
Section 4 requires the Secretary of the Treasury to consult with the Secretary of Health and Human Services, the Secretary of Defense, and the Director of National Intelligence when defining the parameters of biotechnology.
-
Section 5 requires the Secretary of Defense to submit a report within 60 days assessing whether United States capital flows into China's biotechnology sector negatively affect United States national security and military readiness.
Potential Negative Impacts for People
The provided text of the bill does not explicitly detail any negative impacts or burdens for individuals or groups of people in the United States.
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Tap or hover a score for the reason it gave.
- Governance And Ideology
- Does this give the federal government more power? — The bill expands federal oversight and regulatory authority regarding outbound investments in the biotechnology sector. Does this make what the government does easier for the public to see? — The bill mandates comprehensive reporting to congressional committees on capital flows and national security risks.
- Education And Technology
- Does this make patent and copyright rules fairer? — The legislation protects United States pharmaceutical intellectual property and prevents its strategic transfer to foreign adversaries.
- Healthcare
- Does this make the country readier for the next outbreak? — The bill enhances national biosecurity and pharmaceutical supply chain independence by restricting outbound investments in biotechnology.
- 6/2/2026
- Referred to the House Committee on Financial Services.
- 1 Cosponsor added.
- Introduced in House
Debbie DingellDemocrat · Michigan